Spike S1 (B.1.351, Beta Variant), Avi-His-Tag (SARS-CoV-2) Recombinant

• Background:

  SARS-COV-2 Variant B.1.351 was first identified in the fall of 2020 in the Republic of South Africa. This variant, also known as 501Y.V2, has many mutations which may lead to higher transmissibility and infectivity. In particular, the B.1.351 variant contains three mutations within the RBD region of the Spike S1 protein: K417N, E484K, and N501Y. Investigating the effect of mutations on viral replication and pathogenesis will be critical for developing effective strategies for vaccines and antibody therapies against COVID-19.

• Description:

  Recombinant SARS-CoV-2 Spike protein, S1 subunit encompassing amino acids 16-685. This protein corresponds to SARS-CoV-2 Variant B.1.351, also known as variant Beta originally identified in South Africa, and contains mutations L18F, D80A, D215G, R246I, K417N, E484K, N501Y, and D614G. It also contains a C-terminal Avi-Tag™ followed by a C-terminal His-tag (6xHis) . The recombinant protein was affinity purified.

• UniProt:

  P0DTC2

• Tag:

  C-terminal Avi-His-Tag

• Purity:

  ≥ 90%

• Shipping Conditions:

  -80°C

• Storage Conditions:

  At least 6 months at -80°C.

• Calculated Molecular Weight:

  78 kDa + glycans

• Formulation:

  8mM phosphate, pH 7.4,110mM NaCl, 2.2mM KCl, and 20% glycerol.

• Glycosylation:

  This protein runs at higher MW by SDS-PAGE due to glycosylation.